Placebo News and Research

RSS

Molnupiravir reduces hospitalizations and deaths in at-risk, unvaccinated adults with COVID

In a recent phase III study published in the New England Journal of Medicine, researchers demonstrated that oral molnupiravir was effective in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapy among non-vaccinated, non-hospitalized adults at-risk for severe illness.

8 Jun 2022

Study finds added benefits of molnupiravir for non-hospitalized COVID-19 patients

In a recent investigation published in the Annals of Internal Medicine journal, scientists demonstrated the positive impacts of molnupiravir among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients and the healthcare sector apart from lowering disease-linked deaths and hospitalizations in at-risk cohorts.

7 Jun 2022

Taking everolimus post-surgery can improve outcomes in patients with high-risk renal cell carcinoma

In a study of patients with high-risk renal cell carcinoma, those who took the drug everolimus daily for up to one year after surgery lived longer without their disease returning (recurrence-free survival, or RFS) than those who did not take everolimus, although the results narrowly missed the clinical trial's prespecified level for statistical significance.

4 Jun 2022

Ibrutinib plus chemoimmunotherapy prolonged progression-free survival in previously untreated mantle cell lymphoma patients

Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society of Clinical Oncology Annual Meeting.

3 Jun 2022

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

A large randomized, placebo-controlled clinical trial led by the National Institutes of Health shows that treating adults hospitalized with COVID-19 with infliximab or abatacept - drugs widely used to treat certain autoimmune diseases - did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths.

2 Jun 2022

NIH sponsors the trial of monoclonal antibody to prevent asthma exacerbations in urban youth

The National Institutes of Health has launched a clinical trial testing whether a monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighborhoods.

2 Jun 2022

The effectiveness of nirmatrelvir therapy for preventing mortality and hospitalizations due to COVID-19 in high-risk patients during the Omicron surge

Researchers evaluated how effective nirmatrelvir is in preventing COVID-19-associated death and hospitalization in high-risk patients.

2 Jun 2022

Aromatherapy can help control pain and reduce opioid consumption, preliminary study suggests

Aromatherapy reduces post-surgical opioid use by half in hip replacement patients anxious before their operation, according to a new preliminary study being presented at the annual meeting of the European Society of Anaesthesiology and Intensive Care (ESAIC) in Milan, Italy (4-6 June).

2 Jun 2022

Newer class of antidiabetic drugs reduced risk of hospitalization for heart failure

In cardiovascular outcome trials among adults with type 2 diabetes (T2D), sodium-glucose co-transporter 2 inhibitors (SGLT-2i) have shown therapeutic promise, including reduced risk of hospitalization for heart failure compared to placebo.

1 Jun 2022

Combination bNAb therapy may offer a future alternative to daily ART for people living with HIV

Individuals with HIV who began taking antiretroviral therapy (ART) in the early stages of infection achieved a lengthy period of HIV suppression without ART after receiving two broadly neutralizing anti-HIV antibodies (bNAbs), according to a small study published today in the journal Nature.

1 Jun 2022

The effectiveness of tixagevimab/cilgavimab for prevention of SARS-CoV-2 infection and severe disease among immunocompromised patients

A recent article assessed the potency of tixagevimab/cilgavimab in averting SARS-CoV-2 infection in vaccinated immunocompromised people.

31 May 2022

Highest medicinal dose of cannabidiol is driver-safe, study confirms

Ensitrelvir demonstrates swift SARS-CoV-2 clearance and safety among individuals with asymptomatic, mild, or moderate SARS-CoV-2 infections

Researchers reported findings that assessed the safety and efficacy of Ensitrelvir among patients with asymptomatic or mild-to-moderate SARS-CoV-2 infection in Japan.

20 May 2022

Placebo News and Research

Molnupiravir reduces hospitalizations and deaths in at-risk, unvaccinated adults with COVID

Study finds added benefits of molnupiravir for non-hospitalized COVID-19 patients

Taking everolimus post-surgery can improve outcomes in patients with high-risk renal cell carcinoma

Ibrutinib plus chemoimmunotherapy prolonged progression-free survival in previously untreated mantle cell lymphoma patients

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

NIH sponsors the trial of monoclonal antibody to prevent asthma exacerbations in urban youth

The effectiveness of nirmatrelvir therapy for preventing mortality and hospitalizations due to COVID-19 in high-risk patients during the Omicron surge

Aromatherapy can help control pain and reduce opioid consumption, preliminary study suggests

Newer class of antidiabetic drugs reduced risk of hospitalization for heart failure

Combination bNAb therapy may offer a future alternative to daily ART for people living with HIV

The effectiveness of tixagevimab/cilgavimab for prevention of SARS-CoV-2 infection and severe disease among immunocompromised patients

Highest medicinal dose of cannabidiol is driver-safe, study confirms

Researchers evaluate atovaquone as a COVID-19 treatment

Vitamin D supplements have no clinically meaningful effect in people at high risk of type 2 diabetes

Key immunological changes that support peanut allergy remission in children discovered

Changes in dopamine levels in the brain affect emotion-recognition

Widely used Type 2 diabetes drug does not prevent breast cancer spread, landmark trial finds

Sustained weight loss can help improve semen quality in men with obesity

Medication, lifestyle intervention effective in preventing Type 2 diabetes, but not cardiovascular disease

Ensitrelvir demonstrates swift SARS-CoV-2 clearance and safety among individuals with asymptomatic, mild, or moderate SARS-CoV-2 infections

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News